[ad_1]
good news? The vaccine can still greatly reduce the risk of hospital admission due to the Delta variant. The Scottish study found that the Pfizer/BioNTech vaccine provided 79% protection, two weeks from the second dose, while the Oxford/AstraZeneca vaccine provided 60% protection. Researchers say the lower ratio may be because the Oxford/AstraZeneca vaccine takes longer to develop immunity.
However, research Public Health UK released shortly More hopeful. The study found that the Pfizer/BioNTech vaccine can provide 96% hospitalization protection after two injections, while the Oxford/AstraZeneca vaccine is 92% effective in preventing hospitalization after two injections. in conclusion? This further demonstrates the importance of ensuring that as many people as possible are vaccinated, and they are all vaccinated.
Infectious: According to the Department of Public Health, the transmission rate of the Delta variant indoors is 64% higher than that of the Alpha variant.
This data, combined with the admission data, is the reason why the UK has postponed plans to remove most of the remaining covid-19 restrictions by one month. It is hoped that these additional weeks will provide enough time to boost the number of fully vaccinated adults. Although more than 70% of British adults have received a single dose of the vaccine, only more than half have received both vaccines at the same time.
The biggest fear: From the very beginning of the vaccination plan, there has been concern that as the virus evolves and adapts, the current vaccines will become less effective. This situation is called “Vaccine escape.” For now, this does not seem to happen. But in the end we will need new vaccines designed to deal with mutations more precisely.
[ad_2]
Source link
